CoChat

Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas

Open access
Capdevila, Jaume, Arqués, Oriol, Hernández Mora, Jose Ramón, Matito, Judit, Caratù, Ginevra, Mancuso, Francesco M., Landolfi, Stefania, Barriuso, Jorge, Jimenez-Fonseca, Paula, Lopez Lopez, Carlos, Garcia-Carbonero, Rocio, Hernando, Jorge, Matos, Ignacio, Paolo, Nuciforo, Hernández-Losa, Javier, Esteller, Manel, Martínez-Cardús, Anna, Tabernero, Josep, Vivancos, Ana, Palmer, Héctor G. · 2020 · Clinical Cancer Research
Cited by 39

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Purpose: The limited knowledge of the molecular alterations that characterize poorly differentiated neuroendocrine carcinomas has limited the clinical development of targeted agents directed to driver mutations. Here we aim to identify new molecular targets in colon neuroendocrine carcinomas (co-NEC) and proof the efficacy of matching drugs. Experimental Design: We performed a multi-omic analysis of co-NEC to identify genetic or epigenetic alterations that could be exploited as effective drug targets. We compared co-NEC samples with colorectal carcinomas (CRC) to identify neuroendocrine-specific traits. Patients with co-NEC and patient-derived xenografts were treated with a BRAFV600E-blocking drug to demonstrate sensitivity. Results: co-NEC and CRC are similar in their mutational repertoire, although co-NECs are particularly enriched in BRAFV600E mutations. We report for the first time that V600EBRAF-mutant co-NECs may benefit from BRAF inhibition in monotherapy and how EGFR status is essential to predict innate sensitivity and acquired resistance by a differential methylation of its gene regulatory regions. Conclusions: The identification of V600E BRAF mutations in high-grade co-NECs has allowed the description of radiological responses to combination therapy of BRAF and MEK inhibitors in basket clinical trials. However, the molecular rationale for this treatment combination was based on the presence of the BRAF mutation and the efficacy observed in other cancer types such as melanoma. Future drug development in this setting should test BRAF inhibitors upfront and the addition of anti-EGFR antibodies instead of MEK inhibitors for an efficient blockade of acquired resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-19-1266

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 39

Metadata

Authors
Capdevila, J., Arqués, O., Hernández Mora, J. R., Matito, J., Caratù, G., Mancuso, F. M., Landolfi, S., Barriuso, J., Jimenez-Fonseca, P., Lopez Lopez, C., Garcia-Carbonero, R., Hernando, J., Matos, I., Paolo, N., Hernández-Losa, J., Esteller, M., Martínez-Cardús, A., Tabernero, J., Vivancos, A., & Palmer, H. G.
Venue
Clinical Cancer Research
Published
2020-02-14
Volume
26
Issue
4
Pages
902-909
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2985970369
Cited by
39
References
2
FWCI
2.98
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-1266
The paper
Capdevila, J., Arqués, O., Hernández Mora, J. R., Matito, J., Caratù, G., Mancuso, F. M., Landolfi, S., Barriuso, J., Jimenez-Fonseca, P., Lopez Lopez, C., Garcia-Carbonero, R., Hernando, J., Matos, I., Paolo, N., Hernández-Losa, J., Esteller, M., Martínez-Cardús, A., Tabernero, J., Vivancos, A., & Palmer, H. G. (2020). Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-1266

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.